Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate...

Prof Josep Llovet - Hospital Clinic Barcelona, Barcelona, Spain

TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate stage liver cancer ( Prof Josep Llovet - Hospital Clinic Barcelona, Barcelona, Spain )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2...

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates...

Prof Nicolas Girard - Institut Curie, Paris, France

Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates improved clinical benefit in NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Trastuzumab deruxtecan effective against brain metastases in HER2-positive...

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear cell RCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Patient reported outcomes for telisotuzumab vedotin in c-Met protein...

Prof Nicolas Girard - Institut Curie, Paris, France

Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Nivolumab plus ipilimumab improves efficacy versus standard of care in non...

Prof Lothar Bergmann - University Hospital Frankurt, Frankfurt am Main, Germany

Nivolumab plus ipilimumab improves efficacy versus standard of care in non-clear-cell renal cell carcinomas ( Prof Lothar Bergmann - University Hospital Frankurt, Frankfurt am Main, Germany )

Breastfeeding after breast cancer is safe

Dr Eva Blondeaux - Ospedale San Martino, Genova, Italy

Breastfeeding after breast cancer is safe ( Dr Eva Blondeaux - Ospedale San Martino, Genova, Italy )

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival...

Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach...

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC ( Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany )

Repeat immune checkpoint inhibitor therapy not recommended for aRCC

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Repeat immune checkpoint inhibitor therapy not recommended for aRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Intraoperative radiotherapy at Fortis Healthcare Hospital

Dr Nisha Vishnu - Fortis Healthcare & MACs Clinic, Bangalore, India

Intraoperative radiotherapy at Fortis Healthcare Hospital ( Dr Nisha Vishnu - Fortis Healthcare & MACs Clinic, Bangalore, India )

More from ecancer